Yang Y, Foster V, Marlowe S, Stevenson S, Alexander I, Foster R
Eye (Lond). 2025; .
PMID: 40011741
DOI: 10.1038/s41433-025-03688-3.
Hufnagel H, Lahmann C, Pauleikhoff L, Lange C
Ophthalmologie. 2025; 122(3):162-169.
PMID: 39820495
DOI: 10.1007/s00347-024-02179-2.
Liang C, Xu Y, Xia Q, Xiao D, Gu J, Zhu X
Sci Rep. 2024; 14(1):12718.
PMID: 38830921
PMC: 11148059.
DOI: 10.1038/s41598-024-62863-w.
Misawa N, Honda S
Sci Rep. 2023; 13(1):22981.
PMID: 38151501
PMC: 10752866.
DOI: 10.1038/s41598-023-50196-z.
Zola M, Bousquet E, Bourges J, Azan F, Zhao M, Jaworski T
Sci Rep. 2023; 13(1):14111.
PMID: 37644063
PMC: 10465571.
DOI: 10.1038/s41598-023-41126-0.
Unraveling the Puzzle of Central Serous Chorioretinopathy: Exploring Psychological Factors and Pathophysiological Mechanisms.
Sesar A, Pusic Sesar A, Jurisic D, Cvitkovic K, Cavar I
Med Sci Monit. 2023; 29:e941216.
PMID: 37515320
PMC: 10395186.
DOI: 10.12659/MSM.941216.
Primary hyperaldosteronism in Acute Central Serous Chorioretinopathy: a real need for screening?.
Valverde-Megias A, Montolio-Marzo E, Runkle I, Fernandez-Vigo J
Graefes Arch Clin Exp Ophthalmol. 2023; 261(11):3193-3200.
PMID: 37490105
DOI: 10.1007/s00417-023-06185-z.
Detection of macular ganglion cell complex loss and correlation with choroidal thickness in chronic and recurrent central serous chorioretinopathy.
Liu Y, Wu B, Wang Y, Chen S
Int J Ophthalmol. 2023; 16(4):579-588.
PMID: 37077495
PMC: 10089900.
DOI: 10.18240/ijo.2023.04.12.
High Levels of C-Reactive Protein with Low Levels of Pentraxin 3 as Biomarkers for Central Serous Chorioretinopathy.
Bousquet E, Chenevier-Gobeaux C, Jaworski T, Torres-Villaros H, Zola M, Mantel I
Ophthalmol Sci. 2023; 3(3):100278.
PMID: 36950301
PMC: 10025279.
DOI: 10.1016/j.xops.2023.100278.
Biometric Risk Factors for Central Serous Chorioretinopathy.
Gawecki M, Grzybowski A, Swiech A
Ophthalmol Ther. 2023; 12(2):1327-1338.
PMID: 36840908
PMC: 10011280.
DOI: 10.1007/s40123-023-00687-z.
Central serous chorioretinopathy: Pathophysiology, systemic associations, and a novel etiological classification.
Jain M, Mohan S, van Dijk E
Taiwan J Ophthalmol. 2023; 12(4):381-393.
PMID: 36660127
PMC: 9843580.
DOI: 10.4103/2211-5056.362601.
Pupillary Responses Reveal Autonomic Regulation Impairments in Patients With Central Serous Chorioretinopathy.
Zhou X, Fukuyama H, Okita Y, Kanda H, Yamamoto Y, Araki T
Invest Ophthalmol Vis Sci. 2022; 63(10):2.
PMID: 36066317
PMC: 9463716.
DOI: 10.1167/iovs.63.10.2.
Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses.
Felipe C, Biancardi A, Civile V, Junior N, Serracarbassa P, Koike M
Int J Retina Vitreous. 2022; 8(1):34.
PMID: 35672807
PMC: 9172176.
DOI: 10.1186/s40942-022-00385-1.
Clinical Characteristics and Multimodal Imaging Findings of Central Serous Chorioretinopathy in Women versus Men.
Bousquet E, Torres-Villaros H, Provost J, Elalouf M, Gigon A, Mantel I
J Clin Med. 2022; 11(6).
PMID: 35330031
PMC: 8954406.
DOI: 10.3390/jcm11061706.
Mid-Phase Hyperfluorescent Plaques Seen on Indocyanine Green Angiography in Patients with Central Serous Chorioretinopathy.
Bousquet E, Provost J, Zola M, Spaide R, Mehanna C, Behar-Cohen F
J Clin Med. 2021; 10(19).
PMID: 34640543
PMC: 8509799.
DOI: 10.3390/jcm10194525.
Post-Traumatic Stress Disorder Is a Significant Risk Factor for Central Serous Chorioretinopathy in Male Veterans.
Gundlach B, Tsui I
Am J Mens Health. 2021; 15(5):15579883211034990.
PMID: 34546136
PMC: 8461129.
DOI: 10.1177/15579883211034990.
Sharing the Same Perspective. Mental Disorders and Central Serous Chorioretinopathy: A Systematic Review of Evidence from 2010 to 2020.
Pandolfo G, Genovese G, Bruno A, Palumbo D, Poli U, Gangemi S
Biomedicines. 2021; 9(8).
PMID: 34440271
PMC: 8394052.
DOI: 10.3390/biomedicines9081067.
Personality Traits, Stress, and Emotional Intelligence Associated with Central Serous Chorioretinopathy.
Pusic Sesar A, Sesar A, Bucan K, Sesar I, Cvitkovic K, Cavar I
Med Sci Monit. 2021; 27:e928677.
PMID: 33423036
PMC: 7805417.
DOI: 10.12659/MSM.928677.
Increased Risk of Central Serous Chorioretinopathy among Patients with Nonorganic Sleep Disturbance.
Tien P, Lai C, Lin C, Chen W, Lin P, Muo C
J Ophthalmol. 2020; 2020:1712503.
PMID: 32104592
PMC: 7038385.
DOI: 10.1155/2020/1712503.
Central Serous Chorioretinopathy: Pathogenesis and Management.
Semeraro F, Morescalchi F, Russo A, Gambicorti E, Pilotto A, Parmeggiani F
Clin Ophthalmol. 2019; 13:2341-2352.
PMID: 31819359
PMC: 6897067.
DOI: 10.2147/OPTH.S220845.